Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

Abal; Ayhan Bilir; Bilir; Bilir; Cade; Cho; Di Cristofano; Erguven; Ezgi Ermis; Ha; Jemal; Lax; Madeddu; Miller; Mine Erguven; Mine Sencan; Mitsuhashi; Muramatsu; Nishio; Nuray Yazihan; Orrenius; Rawnaq; Salvatierra; Ustach; Vidal; Waller; Wang; Yang; Zhang; Zhu

Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

Authors: Abal
Ayhan Bilir
Bilir
Bilir
Cade
Cho
Di Cristofano
Erguven
Ezgi Ermis
Ha
Jemal
Lax
Madeddu
Miller
Mine Erguven
Mine Sencan
Mitsuhashi
Muramatsu
Nishio
Nuray Yazihan
Orrenius
Rawnaq
Salvatierra
Ustach
Vidal
Waller
Wang
Yang
Zhang
Zhu
Publication date: 1 January 2011
Publisher: Korean Society of Gynecologic Oncology and Colposcopy
Doi

Abstract

Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Crossref

info:doi/10.3802%2Fjgo.2011.22...

Last time updated on 04/12/2019

İstanbul Üniversitesi Açık Erişim Sistemi

oai:http://acikerisim.istanbul...

Last time updated on 19/10/2022